Fermentalg Reports Revenue of €9.6M as of End-September 2025

Steady Financial Performance

Fermentalg recorded unaudited revenue of €9.6 million as of the end of September 2025. The company maintains its double-digit growth target for the year, aiming to reach around €13 million, compared to €11.5 million recorded in 2024. This maintenance of forecasts is supported by the launch of new products, including a natural blue dye, the acquisition of strategic clients in higher-margin market segments, geographical expansion, and continuous optimization of production costs.

Expansion Beyond Dietary Supplements

The year 2025 was marked by Fermentalg's expansion beyond dietary supplements into infant nutrition, a sector facing sustainability challenges due to the ecological transition. The company's flagship product, the Origins™ range, now accounts for about 40% of sales divided between infant nutrition and aquaculture, with the remainder coming from dietary supplements. These advances were made possible by improved industrial performance and reduced production costs. In this uncertain economic environment, cumulative revenue remained stable, thus opening up interesting prospects for the future.

International Expansion and New Partnerships

Fermentalg continues its international expansion by entering new markets. After securing access to the North American market, the company has entered into a partnership with the Chinese group SIRIO, a pharmaceutical subcontractor, to supply algal-origin DHA. Fermentalg is also preparing for the launch of its natural blue dye, Galdieria Blue, recently approved by the US FDA. Production of the first industrial batches is underway, with sales planned from 2026.